Soluble immune checkpoints in lung cancer: linking prognostic signatures to immunotherapy response - a meta-analysis
Abstract
Introduction: Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related death, with most patients diagnosed at advanced, unresectable stages. Although immune-checkpoint inhibitors have transformed the therapeutic landscape, only a subset of patients achieves meaningful and sustained benefit. In this context, circulating soluble immune-checkpoints, particularly soluble PD-L1 (sPD-L1) have emerged as promising non-invasive biomarkers with potential prognostic and predictive value.
Methods: To clarify their relevance, we conducted a systematic review and meta-analysis of studies published between 2015 and 2025, evaluating the association between serum levels of these biomarkers and clinical outcomes in NSCLC. A total of 20 studies including 1967 patients were analyzed, despite heterogeneity in study design and treatment regimens.
Results: Lower baseline sPD-L1 levels consistently correlated with longer progression-free (PFS: random effect model with a pooled HR of 2.26 [95% CI: 1.77-2.87, p < 0.0001]) and overall survival (OS: random effect model with a pooled HR of 2.04 [95% CI 1.55-2.68, p < 0.0001]), whereas elevated concentrations were frequently observed in males, smokers, individuals with advanced disease, and those with liver metastases. Associations between soluble checkpoints and tumor histology, mutational status, or tissue PD-L1 expression varied widely across studies.
Conclusions: Overall, our findings highlight baseline sPD-L1 with a…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,967 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.